COMMUNIQUÉS West-GlobeNewswire

Aptinyx to Present at 8th Annual SVB Leerink Global Healthcare Conference

22/02/2019 - 14:00

EVANSTON, Ill., Feb. 22, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, [...]

Krystal Biotech to Present at the 8th Annual SVB Leerink Global Healthcare Conference

22/02/2019 - 14:00

PITTSBURGH, Feb. 22, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin [...]

Alder BioPharmaceuticals® Submits Biologics License Application to the U.S. Food and Drug Administration for Eptinezumab

22/02/2019 - 14:00

Significant milestone toward the commercialization of eptinezumab, the first quarterly infusion therapy for migraine prevention BOTHELL, Wash., Feb. 22, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: [...]

Calithera to Participate in the 8th Annual SVB Leerink Global Healthcare Conference

22/02/2019 - 14:00

SOUTH SAN FRANCISCO, Calif., Feb. 22, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the [...]

Obalon Announces Fourth Quarter and Full Year 2018 Financial Results

22/02/2019 - 14:00

SAN DIEGO, Feb. 22, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon [...]

Chimerix Presents Results from Post-hoc Analysis of Phase 3 Study

22/02/2019 - 14:00

Decreased HHV-6 Reactivation Observed Among Oral Brincidofovir Allogeneic Hematopoietic Cell Transplantation Recipients Results to be Presented at Transplantation and Cellular Therapy Meetings of ASBMT and CIBMTR 2019 [...]

Voyager Therapeutics and AbbVie Announce Collaboration to Develop Vectorized Antibodies to Treat Parkinson’s Disease and Other Synucleinopathies

22/02/2019 - 14:00

Deal expands collaborative efforts on vectorized antibodies to target pathological species of alpha-synuclein Voyager to receive $65 million upfront and up to $245 million in preclinical and Phase 1 option payments as [...]

Principia Biopharma Announces the Acceptance of Data from Phase 2 Pemphigus Vulgaris Trial as a Late-Breaking Presentation at 2019 American Academy of Dermatology Meeting

22/02/2019 - 14:00

SOUTH SAN FRANCISCO, Calif., Feb. 22, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with [...]

Radient Technologies Inc. Files 17 Provisional Patent Applications for Innovating Cannabinoid Consumption Products and Devices

22/02/2019 - 13:30

EDMONTON, Alberta, Feb. 22, 2019 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) ( TSX Venture: RTI ; OTCQX: RDDTF ) is pleased to announce it has filed an additional 17 provisional patent [...]

Strongbridge Biopharma plc Announces Annual General Meeting of Shareholders

22/02/2019 - 13:30

DUBLIN, Ireland and TREVOSE, Pa., Feb. 22, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of [...]

TG Therapeutics, Inc. Announces Data Presentation at the Upcoming Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Annual Meeting

22/02/2019 - 13:30

NEW YORK, Feb. 22, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the final Phase 2 data from the multicenter trial of ublituximab (TG-1101), the Company’s novel glycoengineered anti [...]

BrainStorm Announces First Contracted U.S. Clinical Site for Phase 2 Progressive MS Study

22/02/2019 - 13:30

Phase 2 Open-Label Trial of Autologous MSC-NTF Cell Therapy (NurOwn®) in Progressive MS Patients will Begin Enrollment in Early 2019 NEW YORK and CLEVELAND, Feb. 22, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics [...]

Vectra® Study Published in the Journal Current Medical Research & Opinion

22/02/2019 - 13:05

Vectra Test Significantly Outperforms DAS28-CRP and CRP and Is the Best Predictor of Joint Damage in Patients with Rheumatoid Arthritis SALT LAKE CITY, Feb. 22, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: [...]

BeiGene to Present at the 8th SVB Leerink Global Healthcare Conference

22/02/2019 - 13:00

CAMBRIDGE, Mass. and BEIJING, China, Feb. 22, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative [...]

LogicBio Therapeutics Appoints Kenneth Huttner, M.D., Ph.D., as Senior Vice President, Head of Clinical Development

22/02/2019 - 13:00

CAMBRIDGE, Mass., Feb. 22, 2019 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases, today announced the appointment of [...]

R1 RCM Reports Fourth Quarter and Full Year 2018 Results

22/02/2019 - 12:30

CHICAGO, Feb. 22, 2019 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-enabled revenue cycle management services to healthcare providers, today announced results for the three months and [...]

Momenta Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results

22/02/2019 - 12:30

-- Ended 2018 with a cash position of $449.0 million -- -- Phase 2 trials of M281 in myasthenia gravis (MG) and hemolytic disease of the fetus and newborn (HDFN) underway; First healthy volunteer dosed in Phase 1/2 [...]

HMS Reports Fourth Quarter and Full Year 2018 Financial Results

22/02/2019 - 12:00

Record 4Q’18 Total Revenue of $155.8 Million and Record Full Year 2018 Revenue of $598.3 Million 4Q’18 GAAP EPS of $0.38 Per Diluted Share, Including Discrete Tax Benefits of $0.17 Per Diluted Share 4Q’18 Adjusted EPS [...]

Announcement no. 2/2019 - Share Buyback Programme

22/02/2019 - 11:20

Announcement no. 2/2019 22 February 2019 Coloplast initiates the second part of the DKK 1bn share buy-back programme Coloplast A/S is initiating the second part of the share buy-back programme totalling up to DKK 1bn, [...]